Known targets — ChEMBL curated mechanism
PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9
The experimentally established mechanism targets of Marizomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 10/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 10/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 9/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 9/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 9/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 9/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 9/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 9/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 9/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 9/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 9/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 9/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 9/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 9/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 9/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 9/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 9/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marizomib SCHEMBL6379031 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL16299707 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL16727767 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL22590161 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL23612709 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL6378694 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL23249771 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL8163424 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL23612710 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Marizomib SCHEMBL22203978 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060008852-A1 | Marine actinomycete taxon for drug and fermentation product discovery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-01-12 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250186469-A1 | THERAPEUTIC AGENT FOR OVARIAN CLEAR CELL CARCINOMA | JSR CORPORATION (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4566628-A1 | THERAPEUTIC AGENT FOR OVARIAN CLEAR CELL CARCINOMA | JSR Corporation (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024029608-A1 | THERAPEUTIC AGENT FOR OVARIAN CLEAR CELL CARCINOMA | JSR株式会社 | 2024-02-08 | — | — | WO | disclosed |
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RAMBAM MED-TECH LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| CN-116406294-A | Tyrosine, tryptophan and phenylalanine as mTOR agonists modulating proteasome kinetics, compositions, methods and uses thereof in therapy, and methods of prognosis of drug resistance | 技术研发基金会有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4178563-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS MTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | Technion Research & Development Foundation Ltd. (IL) | 2023-05-17 | — | — | EP | disclosed |
| US-20220305132-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-09-29 | — | — | US | disclosed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20080160590-A1 | SALT FORMULATIONS FOR THE FERMENTATION OF MARINE MICROORGANISMS | CELGENE INTERNATIONAL II SARL (CH) | 2008-07-03 | — | — | US | disclosed |
| WO-2006060809-A9 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070155815-A1 | administering an antiproliferative agents, anticarcinogenic agents, obtained from the fermentation of marine actinomyces strains; low molecular weight, high pharmaceutical potency, and selectivity for cancer cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-07-05 | — | — | US | disclosed |
| US-20070155815-A1 | administering an antiproliferative agents, anticarcinogenic agents, obtained from the fermentation of marine actinomyces strains; low molecular weight, high pharmaceutical potency, and selectivity for cancer cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-07-05 | — | — | US | disclosed |
| WO-2007056335-A2 | METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7176233-B2 | Fermentation product of marine actinomyces; antiproliferative agents; anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176233-B2 | Fermentation product of marine actinomyces; antiproliferative agents; anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176232-B2 | Fermentation product of marine actinomyces strains; antiproliferative agents; anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176232-B2 | Fermentation product of marine actinomyces strains; antiproliferative agents; anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2005003137-A1 | SALINOSPORAMIDES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RPTOR, PSMG3, MTOR | PSMB5 55/4885PSMB1 32/4885PSMB2 39/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | PSMB5 4308/4885PSMB1 3890/4885PSMB2 4166/4885 |
| US-20220305132-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | CD22, BTK, CD79B | PSMB5 2979/4885PSMB1 2959/4885PSMB2 2614/4885 |
| US-20070155815-A1 | administering an antiproliferative agents, anticarcinogenic agents, obtained from the fermentation of marine actinomyces strains; low molecular weight, high pharmaceutical potency, and selectivity for cancer cells | ERG28, MGAM, ACP1 | PSMB5 2294/4885PSMB1 3078/4885PSMB2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.